Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Amfetamine 10mg / Dexamfetamine 10mg modified-release caps
0404000L0AAAFAF
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amfetamine 12.5mg / Dexamfetamine 12.5mg MR caps
0404000L0AABFBF
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amfetamine 2.5mg / Dexamfetamine 2.5mg modified-release caps
0404000L0AABDBD
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amfetamine 5mg / Dexamfetamine 5mg modified-release capsules
0404000L0AABHBH
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amfetamine 5mg / Dexamfetamine 5mg tablets
0404000L0AAAVAV
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amfetamine 7.5mg / Dexamfetamine 7.5mg modified-release caps
0404000L0AABEBE
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amgevita 20mg/0.4ml inj pre-filled syringes
1001030S0BCACAI
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita 40mg/0.8ml inj pre-filled syringes
1001030S0BCAAAA
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita 40mg/0.8ml solution for injection pre-filled pens
1001030S0BCABAB
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 20mg/0.2ml inj pre-filled syringes
1001030S0BCAHAF
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 40mg/0.4ml inj pre-filled syringes
1001030S0BCAGAE
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 80mg/0.8ml inj pre-filled pens
1001030S0BCADAH
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amgevita HCF 80mg/0.8ml inj pre-filled syringes
1001030S0BCAEAG
|
Amgevita | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Amglidia 0.6mg/ml oral suspension with 1ml oral syringe
0601021H0BNAAAP
|
Amglidia | Glibenclamide | Endocrine System | No data available |
|
Amglidia 0.6mg/ml oral suspension with 5ml oral syringe
0601021H0BNABAP
|
Amglidia | Glibenclamide | Endocrine System | No data available |
|
Amglidia 6mg/ml oral suspension with 1ml oral syringe
0601021H0BNACAQ
|
Amglidia | Glibenclamide | Endocrine System | No data available |
|
Amglidia 6mg/ml oral suspension with 5ml oral syringe
0601021H0BNADAQ
|
Amglidia | Glibenclamide | Endocrine System | No data available |
|
Amiclav 250mg/125mg tablets
0501013K0BCAAAA
|
Amiclav | Co-amoxiclav (Amoxicillin/clavulanic acid) | Infections | No data available |
|
Amifostine 375mg powder for solution for infusion vials
0801000V0AAAAAA
|
Amifostine | Amifostine | Malignant Disease and Immunosuppression | No data available |
|
Amifostine 500mg powder for solution for infusion vials
0801000V0AAABAB
|
Amifostine | Amifostine | Malignant Disease and Immunosuppression | No data available |
|
Amikacin 500mg/2ml solution for injection vials
0501040C0AAAAAA
|
Amikacin (Parenteral) | Amikacin | Infections | No data available |
|
Amikin 100mg/2ml solution for injection vials
0501040C0BBACAD
|
Amikin | Amikacin | Infections | No data available |
|
Amikin 500mg/2ml solution for injection vials
0501040C0BBAAAA
|
Amikin | Amikacin | Infections | No data available |
|
Amil-Co 5mg/50mg tablets
0202040C0BBAAAA
|
Amil-Co | Co-amilozide (Amiloride hydrochloride/hydrochlorothiazide) | Cardiovascular System | No data available |
|
Amilamont 5mg/5ml oral solution sugar free
0202030C0BFAAAS
|
Amilamont | Amiloride hydrochloride | Cardiovascular System | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.